Navigation Links
Medivation Reports Third Quarter 2010 Financial Results and Provides Corporate Update
Date:11/5/2010

IABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:  Accounts payable

$
5,482$
4,840  Accrued expenses

22,61212,054  Deferred revenue

57,22586,570  Other current liabilities

158800Total current liabilities

85,477104,264Deferred revenue, net of current

150,067166,598Other non-current liabilities

978554Total liabilities

236,522271,416Stockholders' equity:  Preferred stock, $0.01 par value per share;,000,000 shares authorized; no shares issued and outstanding

--  Common stock, $0.01 par value per share;50,000,000 shares authorized; issued and outstanding 34,571,329 shares at September 30, 2010 and 33,823,062 at December 31, 2009

346338  Additional paid-in capital

214,995202,361  Accumulated other comprehensive gain (loss)

3(12)  Accumulated deficit

(207,561)(177,413)Total stockholders' equity

7,78325,274Total liabilities and stockholders' equity

$
244,305$
296,690
'/>"/>

SOURCE Medivation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Medivation Announces Third Quarter 2010 Financial Results Teleconference and Webcast on November 5, 2010
2. Medivation Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 2010
3. Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
4. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
5. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
6. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
7. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
8. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
9. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
10. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
11. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Pa. , Nov. 25, 2014  Unilife Corporation ... of injectable drug delivery systems, today announced that its ... to present at the Piper Jaffray 26th Annual Healthcare ... a.m. EST on Tuesday, December 2, 2014. ... Internet as a "live" listen only Webcast. To listen, ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
(Date:11/26/2014)... DIEGO , Nov. 25, 2014 Halozyme Therapeutics, ... the Piper Jaffray Healthcare Conference in New York ... EDT/10:00 a.m. PDT . Dr. Helen Torley , ... The presentation will be webcast through the "Investors" ... a recording will be made available for 90 days following ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... Delcath Systems, Inc. (Nasdaq: DCTH ) ... Senior Vice President of Medical Device Research and Development ... to the position of Vice President of Pharmaceutical Research ... based in the Company,s Queensbury, New York facility and ...
... Thomson Reuters, a global provider of information ... version of its award-winning Clinical Xpert Navigator ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO) (Logo: http://photos.prnewswire.com/prnh/20090507/NY12658LOGO) ... to access complete patient clinical data — ...
Cached Medicine Technology:Delcath Strengthens Research and Development Team with Key Appointments 2Delcath Strengthens Research and Development Team with Key Appointments 3Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 2Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 3
(Date:11/26/2014)... Rosa, California (PRWEB) November 26, 2014 ... making never before seen reductions in prices of their ... and Liposomal Vitamin D3 . Discounts of ... , GI for Life’s proprietary ColoVite supplement ... board-certified gastroenterologists to promote colon health. One easy-to-take colon ...
(Date:11/26/2014)... 2014 Anthropologists have identified concrete ... and stopping Ebola, improve international support, and pave ... in West Africa. , The report, “Strengthening ... Anthropologists Offer Insights,” will be made public during ... Association (AAA), Fri., Dec. 5, 11 a.m., at ...
(Date:11/26/2014)... 2014 For those with a New Year’s ... MILLS BODYPUMP™ classes at the University of Colorado Anschutz ... been looking for. The 45- 60 minute classes have just ... Wellness Center fitness club memberships. , LES MILLS BODYPUMP™ exercise ... and are aimed at fast results , By focusing ...
(Date:11/26/2014)... of the most important and vital decisions a woman ... choosing the ideal wedding dress and bridesmaid dresses. BellasDress.com ... quality outfits. Today, BellasDress.com has unveiled its new range ... suitable bridesmaid gowns here at discount prices. , Formal ... and highlight all their most beautiful features while drawing ...
(Date:11/26/2014)... of emergency department visits in the United States rose from ... in 2011, according to the U.S. Centers for Disease Control ... were going to ERs with non-urgent medical needs: 96 percent ... hours of arriving at the ER. In 2010, that number ... of patients arrived at the ER after normal business hours ...
Breaking Medicine News(10 mins):Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Royal Blue Bridesmaid Dresses Now Are Available for Christmas at BellasDress.com 2Health News:ER Visits on the Rise, Study Reports 2
... , MONDAY, May 21 (HealthDay News) -- The new blood ... blood clots in high-risk heart patients, a U.S. Food and ... briefing documents that were filed Monday in advance of an ... to vote on whether to recommend approval of Xarelto for ...
... HealthDay Reporter , MONDAY, May 21 (HealthDay News) -- ... helps overweight women lower the levels of certain hormones in ... breast cancer. The findings don,t ... Still, women who take medications to prevent the disease "need ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... be reducing their risk of psoriasis, Harvard University researchers report. ... scaly patches on the skin. Vigorous activity for ... risk by 25 percent to 30 percent, the researchers said. ...
... scientist from the Viral Immunology Center at Georgia State ... of the eye is associated with neovascular age-related macular ... elderly. The scientists found that human cytomegalovirus, a ... growth factor, or VEGF, a signal protein that regulates ...
... A team of scientists has developed a promising new ... shrink and die. The researchers hope that their discovery ... drug that effectively targets unhealthy, cancerous tissue without damaging ... be published in the Journal of Biological Chemistry ...
... went to John Edward Solder, a senior at Staples ... Interrogation of Prefrontal Cortex Dopamine D1 Receptor-Containing Neurons as ... Treat Prefrontal Disorders. The 18-year-old was able to specifically ... to activate dopamine neurons in the prefrontal cortex, a ...
Cached Medicine News:Health News:New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA 2Health News:Dieting May Lower Hormone Levels Tied to Breast Cancer 2Health News:Vigorous Exercise Might Keep Psoriasis at Bay 2Health News:Vigorous Exercise Might Keep Psoriasis at Bay 3Health News:Type of viral infection of eye associated with disease causing blindness in the elderly 2Health News:Strategy discovered to activate genes that suppress tumors and inhibit cancer 2Health News:Strategy discovered to activate genes that suppress tumors and inhibit cancer 3Health News:Optogenetics project takes top NIDA Addiction Science Award 2Health News:Optogenetics project takes top NIDA Addiction Science Award 3Health News:Optogenetics project takes top NIDA Addiction Science Award 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: